中文
R&D Pipelines
Lishan Biotech specializes in the research and development of innovative drugs, creating sustainable value for the enhancement of human life quality. Its core pipeline includes Small Molecule (SM) drugs with globally leading mechanisms of action, as well as Live Biotherapeutic Products (LBP), known as the "third-generation therapy".


Swarming Technology
Swarming is a bacterial motility phenotype characterized by collective cooperative migration behavior, accompanied by adaptive changes in bacterial morphology and metabolic pathways. In the environment of intestinal inflammation, high concentrations of reactive oxygen species, rough interfaces formed by mucosal damage, and high iron ion concentrations caused by bleeding collectively induce the enrichment of facultative anaerobic Swarming bacteria, making them potential biomarkers of intestinal inflammation. Experiments have shown that compared to Swarming phenotype knockout strains, natural Swarming strains are more effective in alleviating intestinal inflammation. At present, Swarming technology has been applied in the treatment of Crohn's disease in the LS-LBP-001 pipeline.
IMicAP Microbial Platform
Lishan Biotech and the Institute of Intelligent Medicine at Fudan University jointly established the "Intelligent Microbiome School Enterprise Joint Laboratory" in 2023. With the knowledge support of the precision medicine knowledge base of the Institute of Intelligent Medicine and the data support of 18 affiliated hospitals, combined with the research results of the company's early participation in the "Human Microbiome Program", they independently developed the Intelligent Microbial Application Platform (IMicAP), obtained national authorized invention patents and international PCT protection, and are committed to becoming a leader in the global "AI+Microbiology" sub field.

Research Articles
Innovation is the driving force behind Lishan Biotech's continuous progress.
News & Events
Company News
Regularly update company updates, follow us for quick access to the latest company news.